Journal of Clinical Oncology · 1999 · 80 citations · 24 references
MedicineOncologyPharmacologyCancer PharmacologyClinical PharmacologyOncology PharmacotherapyCancer BiomarkersHormonal Cancer TherapyHormonal TherapyBreast Cancer Endocrine TherapyBreast Cancer Hormonal TherapyBreast Cancer Hormone TherapyEstrogen MetabolitesEstrogen PharmacologyHormone Biomarkers In CancerHormone Therapy ToxicityLipid Profile Changes
PURPOSE: Tamoxifen administered at 20 mg/d has been shown to decrease breast cancer incidence in at-risk women by 50%, but toxicity may limit its broad use, particularly in postmenopausal women. Because toxicity may be dose-dependent, we studied the biologic activity of low concentrations of tamoxifen to determine the plausibility of a dose reduction. PATIENTS AND METHODS: We measured the blood concentrations of tamoxifen and its main metabolites in a dose titration study in 105 healthy women (placebo, tamoxifen 10 mg on alternate days, tamoxifen 10 mg/d, and tamoxifen 20 mg/d). Drug levels measured after 2 months of treatment were correlated with the changes in surrogate biomarkers of different diseases, including lipid profile, blood cell count, fibrinogen, antithrombin III, osteocalcin, and insulin-like growth factor I, a promising surrogate biomarker of breast cancer. RESULTS: The means (+/- SD) for tamoxifen and N-desmethyltamoxifen (metabolite X) concentrations (ng/mL) were dose-related, being, respectively, 0 and 0 with placebo, 26.8 +/- 15.1 and 43.7 +/- 22.5 with 10 mg every other day, 51.2 +/- 24.1 and 90.7 +/- 48.0 with 10 mg/d, and 136.0 +/- 52.7 and 230.6 +/- 75.0 with 20 mg/d of tamoxifen. At variance, the biomarker changes were of comparable magnitude at any drug concentration except for platelet count and triglycerides levels, the latter showing a trend to an increase with increasing tamoxifen concentrations. CONCLUSION: An 80% reduction in blood concentrations does not seem to affect the activity of tamoxifen on biomarkers of cardiovascular or breast cancer risk and may in fact have a more favorable safety profile. Additional studies are warranted to determine the most appropriate dose of this agent.
24
Bernard Fisher, Joseph P. Costantino, D. Lawrence Wickerham et al. · JNCI Journal of the National Cancer Institute · 1998 · 5.5K citations · Full text
Tamoxifen for early breast cancer: an overview of the randomised trials
The Lancet · 1998 · 4.1K citations
Circulating concentrations of insulin-like growth factor I and risk of breast cancer
Susan E. Hankinson, Walter C. Willett, Graham A. Colditz et al. · The Lancet · 1998 · 1.8K citations
B. Fisher, Joseph P. Costantino, Carol Redmond et al. · JNCI Journal of the National Cancer Institute · 1994 · 1.3K citations
Medicine, Gynecology, Oncology +14